中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | HS856076 |
|---|---|
| 설명 |
Research Grade Afasevikumab (HS856076) is a human monoclonal antibody detecting CTLA-8 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
|
| 종 반응성 | Human |
| 응용 분야 | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 숙주 종 | Human |
| 클론성 | Monoclonal |
| 이소타입 | IgG1-kappa |
| 타겟 | CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A, Cytokine ML-1, IL-17F, IL17F, Interleukin-17F |
| 내독소 수준 | < 10 EU/mg |
| 순도 | >95% as determined by SDS-PAGE. |
| 정제 | Protein A/G purified from cell culture supernatant. |
| 등록번호 | Q16552, Q96PD4 |
| 형태 | Liquid |
| 저장 완충액 | 0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 대체 이름 | MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9 |
| 배경 | Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified. • IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881 • The IL-17 Family of Cytokines in Health and Disease., PMID:30995505 • The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781 • Functional specialization of interleukin-17 family members., PMID:21349428 • Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067 • The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764 • The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481 • Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452 • Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228 • Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332 |
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (HyHEL-10) (HV080407) Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
SEC-HPLC detection for Research Grade Afasevikumab.
Detects IL17A in indirect ELISAs.
SDS-PAGE for Research Grade Afasevikumab.
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
